MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

106.9 0.89

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

105.66

Max

107.53

Galvenie mērījumi
By Trading Economics
Ienākumi	19M 424M
Pārdošana	150M 1.4B
P/E Sektora vidējais	17.253 87.826
Peļņas marža	31.052
Darbinieki	2,617
EBITDA	-75M 507M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-5.3% downside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 9. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.8B 20B
Iepriekšējā atvēršanas cena	106.01
Iepriekšējā slēgšanas cena	106.9

Ziņu noskaņojums

By Acuity

24%

76%

111 / 372 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 9. janv. 22:18 UTC

Tirgus saruna

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. janv. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 9. janv. 21:43 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

2026. g. 9. janv. 20:39 UTC

Tirgus saruna

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

2026. g. 9. janv. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

2026. g. 9. janv. 20:36 UTC

Iegādes, apvienošanās, pārņemšana

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

2026. g. 9. janv. 20:30 UTC

Tirgus saruna

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

2026. g. 9. janv. 20:15 UTC

Tirgus saruna

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

2026. g. 9. janv. 20:07 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 9. janv. 20:07 UTC

Tirgus saruna

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

2026. g. 9. janv. 19:58 UTC

Iegādes, apvienošanās, pārņemšana

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

2026. g. 9. janv. 19:42 UTC

Tirgus saruna

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

2026. g. 9. janv. 19:38 UTC

Iegādes, apvienošanās, pārņemšana

Wolters Kluwer Acquires StandardFusion >WTKWY

2026. g. 9. janv. 19:31 UTC

Peļņas

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

2026. g. 9. janv. 19:28 UTC

Peļņas

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

2026. g. 9. janv. 18:30 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

2026. g. 9. janv. 18:23 UTC

Tirgus saruna

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

2026. g. 9. janv. 17:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 9. janv. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 9. janv. 17:19 UTC

Tirgus saruna

Energy Prices Not Seen Supporting More Drilling -- Market Talk

2026. g. 9. janv. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 9. janv. 17:07 UTC

Tirgus saruna

McDonald's Promotions Appear Successful -- Market Talk

2026. g. 9. janv. 17:06 UTC

Tirgus saruna

Oil Futures on Track for Weekly Gains -- Market Talk

2026. g. 9. janv. 17:05 UTC

Peļņas

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

2026. g. 9. janv. 16:57 UTC

Tirgus saruna

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

2026. g. 9. janv. 16:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 9. janv. 16:46 UTC

Tirgus saruna

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

-5.3% uz leju

Prognoze 12 mēnešiem

Vidējais 100.31 USD -5.3%

Augstākais 125 USD

Zemākais 73 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

111 / 372 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation